

**BME - GROWTH**

Palacio de la Bolsa  
Plaza de la Lealtad, 1  
28014 Madrid

Alicante, 3<sup>rd</sup> of June 2022

**COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.**

Dear Sirs,


Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23<sup>rd</sup> October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

The Company published as privileged information on the 25<sup>th</sup> of January 2021 the resolutions adopted by the Extraordinary General Shareholders' Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue warrants convertible into shares of the Company in favour of Nice & Green, S.A. ("Nice & Green"), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase de share capital by the amount necessary to cover the conversion of said warrants.

On 16<sup>th</sup> February 2022, the Board of Directors adopted a resolution, under the delegation of the Company's Extraordinary General Shareholders' Meeting of January 25<sup>th</sup>, 2021, to carry out the second issue of 48,076,923 warrants convertible into shares of the Company for a maximum conversion amount of €2,500,000 (the "Equity Warrants (FEBRUARY 2022)"), with Nice & Green being the sole subscriber of the issue of the Equity Warrants (FEBRERO 2022).

Nice&Green, on April the 1<sup>st</sup> and May 3<sup>rd</sup>, 13<sup>th</sup>, 19<sup>th</sup> and 27<sup>th</sup> of 2022, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 38,172, 104,558, 237,642, 212,983 and 180,531 Equity Warrants (FEBRUARY 2022) for a total conversion amount of 1,900,000 euros.

As a result of the foregoing, the Company has granted a capital increase title deed to cover the conversion of that said Equity warrants issued. The new shares of the Company are issued, 38,172 shares with an issue price per share of 2.6197 euros, (2.5797 euros as issue premium and 0.04 euros as nominal), 104,558 shares with an issue price per share of 2.3910 euros (2.351 euros as issue premium and 0.04 euros as nominal), 237,642 shares with an issue price per share of 2.3144 euros (2.2744 euros will as issue premium and 0.04 euros as nominal) 212,983 shares with an issue price



per share of 2.3476 euros, (2.3076 euros as issue premium and 0.04 euros as nominal) and 180,531 shares, with an issue price per share of 2.7696 euros (2.7926 euros as issue premium and 0.04 euros as nominal)

Following the above mentioned capital increase, the share capital is set at the sum of 644,690.12 €, represented by 16.117.253 shares of FOUR CENTS OF EURO (€0.04) nominal value each, of the same class, equal, cumulative and indivisible.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

-----

Javier Mira Miró

**Chairman of the Board of Directors**